Does Insurance Cover Zepbound? 2026 Guide

Section 1: What Is Zepbound Approved For?

Zepbound (tirzepatide 2.5 mg through 15 mg once-weekly injection) holds two FDA-approved indications:

• ✓
  Chronic weight management: As an adjunct to reduced-calorie diet and increased physical activity in adults with an initial BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity (hypertension, Type 2 diabetes, dyslipidemia, or obstructive sleep apnea).
• ✓
  Obstructive sleep apnea (OSA): FDA-approved in December 2024 for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity (BMI ≥ 30). This indication creates a distinct coverage pathway on some plans — particularly for Medicare and plans that restrict weight-loss drug coverage.

Section 2: How Coverage Is Typically Structured

Formulary tier placement and coverage rates

When covered, Zepbound typically appears on Tier 3 or Tier 4 (specialty tier), applying higher cost-sharing than preferred-tier drugs. Coverage rates across the major commercial insurers in 2026 reflect significant variation:

Prior authorization criteria

Prior authorization is required under essentially all plans that cover Zepbound. Documentation requirements typically include:

• Current BMI documentation (BMI ≥ 30, or BMI ≥ 27 with qualifying comorbidity)
• Relevant comorbidity diagnosis with ICD-10 codes (hypertension E11.x, T2D E66.x, OSA G47.33)
• Documentation of prior weight-management attempts (typically 3 to 6 months of supervised diet/lifestyle program)
• For OSA indication: sleep study results confirming moderate-to-severe OSA (AHI documentation)
• Prescriber letter of medical necessity
• Patient insurance and demographic information

PA decisions typically take 3 to 7 days. Authorization periods range from 6 months (initial) to 12 months for patients on continuous therapy for 52 or more weeks. Reauthorization may require documentation of clinical progress.

Step therapy

Step therapy requirements for Zepbound weight management coverage vary considerably by plan. Some plans require a documented 6-month trial of a structured behavioral weight-management program before approving Zepbound. Others require prior trial of a different weight-loss medication. Plans that apply step therapy "ST" markers should be queried directly about what specific steps are required and how long each step must be documented.

Section 3: Typical Out-of-Pocket Cost with Insurance

Zepbound's list price is approximately $1,060 to $1,080 per month before insurance. Your actual cost depends on your plan's coverage status and cost-sharing structure:

Section 4: Common Reasons for Denial and How to Appeal

Common denial reasons

• 1
  Formulary exclusion: Your plan does not include Zepbound on its formulary at all, or it was removed (as with CVS Caremark's 2025 removal). A formulary exception request with medical necessity documentation may allow access even when the drug is excluded.
• 2
  BMI or comorbidity criteria not documented: Clinical records did not explicitly establish BMI ≥ 30, or BMI ≥ 27 with a qualifying comorbidity using the correct ICD-10 codes. Explicit diagnosis codes must appear in chart notes, not just the PA form.
• 3
  Lifestyle intervention not documented: Many plans require documented prior participation in a supervised weight-management program (typically 6 months) before approving Zepbound. If this history exists but was not included in the PA submission, resubmitting with complete documentation often resolves the denial.
• 4
  Step therapy not completed: Plan requires prior trial of a specific weight-loss medication before Zepbound. Ask your insurer precisely what medications qualify as a step and how to document failure or intolerance.
• 5
  Medical necessity determination: Automated claim review flagged the prescription without reviewing full clinical context. Requesting a peer-to-peer review between your prescriber and the insurer's medical director can reverse many of these denials.

How to appeal

1. Request the denial letter and identify the specific reason code.
2. Gather documentation that directly addresses the denial: updated BMI measurement, ICD-10 codes for comorbidities, sleep study results if OSA indication applies.
3. Compile a 6-month weight-management history — physician appointments, dietitian visits, or program enrollment records.
4. Have your prescriber write a detailed medical necessity letter citing clinical evidence and patient-specific factors.
5. If the denial is "formulary exclusion," request a formulary exception by demonstrating that covered alternatives are clinically inadequate or contraindicated.
6. Submit the complete appeal within your plan's deadline (typically 60 to 180 days from the denial notice).

Data indicates that over 65% of Zepbound denials are overturned with proper documentation. Having an endocrinologist or obesity medicine specialist involved in the appeal strengthens the clinical argument substantially.

Section 5: Eli Lilly Savings Programs for Zepbound

Eli Lilly operates savings programs that can substantially reduce Zepbound costs for eligible patients:

Section 6: If Your Insurance Does Not Cover Zepbound

Given that more than half of commercial plan members have no Zepbound coverage, telehealth access is a meaningful alternative. These providers use licensed prescribers and ship directly to your home.

Advertising disclosure: The telehealth options below are paid sponsors. We may earn a commission when you sign up. This does not affect your pricing. Listing order does not imply medical recommendation. Always consult a licensed healthcare provider.

Section 7: Frequently Asked Questions